Celyad Oncology reports Q3 results

• Celyad Oncology press release (NASDAQ:CYAD): Q3 as of September 30, 2022, the Company had cash and cash equivalents of €13.4M ($13.1M).
• Net cash burn during the first quarter of 2022 amounted to €1.0M ($1.0M), in line with expectations.
• The Company confirms its previous guidance that its existing cash and cash equivalents should be sufficient to fund operating expenses and capital expenditure requirements up to mid-2023.